Higher plasma cystatin C is associated with mortality after acute respiratory distress syndrome: findings from a Fluid and Catheter Treatment Trial (FACTT) substudy.
Carolyn M HendricksonYuenting D KwongAnnika G BelzerMichael G ShlipakMichael A MatthayKathleen D LiuPublished in: Critical care (London, England) (2020)
Higher plasma levels of cystatin C on enrollment were strongly associated with mortality at 60 days in patients with ARDS with and without AKI identified by creatinine-based definitions. Compared to creatinine, cystatin C may be a better biomarker of kidney function in patients with ARDS and therefore identify patients with multiple organ failure at higher risk of death.
Keyphrases
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- mechanical ventilation
- uric acid
- acute kidney injury
- study protocol
- clinical trial
- intensive care unit
- risk factors
- randomized controlled trial
- health insurance
- phase iii
- metabolic syndrome
- coronary artery disease
- combination therapy
- ultrasound guided